Screening for coronary heart disease: Cardiology through the oncology looking glass

US Preventive Services Task Force. Screening for coronary heart disease: recommendation statement. Ann Intern Med 2004; 190:569–72. Miettinen OS. The modem scientific physician. The useful property of a screening regimen. CMAJ 2001;165:1219–20. Mark DB, Shaw LJ, Lauer MS, O’Malley PG, Heidenreich P. 34th Bethesda Conference: Task Force #5—is atherosclerotic imaging cost effective? From the 34th Bethesda Conference on Atherosclerotic Imaging. J Am Coll Cardiol 2003;41:1906–17. Miettinen OS, Henschke CI, Pasmantier MW, Smith JP, Libby DM, Yankelevitz DF. Mammography screening: no reliable supporting evidence? Lancet 2002;359:404–5. Carter HB. Prostate cancers in men with low PSA levels—must we find them? N Engl J Med 2004;350:2291–4. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129–34. Olsen O, Gotzsche PC. Cochrane review of screening for breast cancer with mammography. Lancet 2001;358:1340–2. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988;297:943–8. Miller AB, Baines CJ, To I, Wall C. Canadian National Breast Screening Study. Breast cancer detection and death rates among women aged 40-49 years (study 1) and 50-59 years (study 2). CMAJ 1992;147:1459–88. Miller AB, To I, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50–59 years. J Natl Cancer Inst 2000;92:1490–9. Miller AB. Screening for breast cancer: a review. Eur J Cancer Clin Oncol 1988;24:49–53. Patz EF, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med 2000;343:1627–33. Yamamoto K, Ohta S, Ito E, Hayashi Y, Asami T, Mabuchi O, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening a 6-months of age: cohort study in seven prefectures in Japan. J Clin Oncol 2002;20:1209–14. Schilling FH, Spix C, Berthold F, Entmann R. Neuroblastoma screening at one year of age. N Engl J Med 2002;346:1047–53. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Soc 1958;53:457–81. Cox D. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187–220. Blackstone E, Naftel D, Turner M. The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information. J Am Stat Assoc 1986;81:615–24. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99–105. Peeters A, Mamum AA, Willekens F. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002;23:458–66. Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Health Tech Assess 1998;2:1–84. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, et al. Recent trends in acute coronary heart disease— mortality, morbidity, medical care and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med 1996;334:884–90. The Multiple Risk Factor Intervention Trial Group. Statistical design considerations in the NHLBI multiple risk factor intervention trial (MRFIT). J Chronic Dis 1977;30:261–75. Acevedo M, Pearce GL, Jacobsen DW, Minor S, Sprecher DL. Serum homocysteine levels and mortality in outpatients with or without coronary artery disease: an observational study. Am J Med 2003;114:685–8. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003;138:891–7. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–65. Wang TJ, Levy D, Benjamin EJ, Vasan RS. The epidemiology of “asymptomatic” left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003;138:907–16. Wilson PEF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–47. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97. Olsen JC, Edmundowicz D, Becker DJ, Kuller LH, Orchard TJ. Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes 2000;49:1571–8. O’Rourke RA, Bmndage BH, Froelicher VF, Greenland P, Grundy SM, Hachamovitch R, et al. ACC/AHA expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 2000;102:126–40. Wong ND, Sciammarella MG, Polk D, Gallagher A, Miranda-Peats L, Whitcomb B, et al. The metabolic syndrome, diabetes, and sub-clinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol 2003;41:1547–53. Kondos GT, Hoff JA, Sevrukov A, Daviglus ML, Garside DB, Devries SS, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 2003; 107:2571–6. Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, et al. Prevention Conference V: beyond secondary prevention—identifying the high-risk patient for primary preven- tion; noninvasive test of atherosclerotic burden: Writing Group III. Circulation 2000;101:E16–22. Raggi P. The use of electron-beam computed tomography as a tool for primary prevention. Am J Cardiol 2001;88(Suppl):28J-32J. Wong ND, Detrano RC, Diamond G, Rezayat C, Mahmoudi R, Chong EC, et al. Does coronary artery screening by electron beam computed tomography motivate potentially beneficial lifestyle behaviors? Am J Cardiol 1996;78:1220–3. Weintraub WS. Coronary artery calcium and cardiac events: is electron-beam tomography ready for prime time? Circulation 2003;107:2528–30. Boyko EJ. Ruling out or ruling in disease with the most sensitive or specific diagnostic test; short cut or wrong turn. Med Decis Making 1994;14:175–9. Smith IE. Screening for lung cancer: time to think positive. Lancet 1999;354:86–7. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Pames HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004;350:2239–46. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125–35. Wilson JF. The promise of disease proteomics: faster detection, diagnosis, and drug development. Ann Intern Med 2004; 140:317–9. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects. Diabetes Care 2004;27:1954–61. Frick M, Karakolcu F, Schnitzer H, Alber HF, Stoeger A, Obrist P, et al. Calcium score as assessed by multi-slice computed tomography does not predict maximum plaque burden: an in vitro study. Heart 2004;90:1057–8. Cadman D, Chambers L, Feldman W, Sackett D. Assessing the effectiveness of community screening programs. JAMA 1984;251:1580–5. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-ethnic Study of atherosclerosis (MESA): objectives and design. Am J Epidemiol 2002;156:871–81.